ERBB2 and breast cancer: This was demonstrated with the study investigating the efficacy of neoadjuvant treatment on inflammatory BC (HER2-negative—BEVERLY 01 or HER2-positive—BEVERLY 02) with non-metastatic patients (M0) or prospective study with M1 BC [94].